Transfusion and Apheresis Support in Sickle Cell Disease

Overview

In sickle cell disease, transfusion is a two-edged tool: when applied in the correct indication, it saves lives by preventing devastating events such as stroke; when applied unnecessarily, it leads to persistent problems such as alloimmunization, iron overload, and hyperviscosity. Understanding this duality forms the essence of transfusion management in the disease.

The purpose of transfusion in this disease is not only to increase oxygen-carrying capacity as in other anemias; the main goal is to prevent vaso-occlusion and related tissue damage by reducing the proportion of cells containing sickling hemoglobin S in circulation. This goal can be achieved in two different ways, and the choice between them is clinically decisive.

In simple transfusion, normal red blood cells are added to the patient; this reduces the hemoglobin S ratio by dilution but also increases total hemoglobin and thus blood viscosity. In exchange transfusion, the patient's own sickled cells are removed and replaced with normal red blood cells; in this way, the hemoglobin S ratio rapidly decreases while total hemoglobin does not rise.

This difference explains why exchange transfusion is preferred in acute and severe events. Viscosity has a special place in this disease and gives rise to a counterintuitive rule: bringing hemoglobin 'to normal' is harmful.

Increasing hemoglobin above a certain level in a patient adapted to chronic anemia decreases blood flow and facilitates occlusion of sickle cells in the microcirculation, paradoxically triggering vaso-occlusive events. Therefore, when setting transfusion targets, both a target for hemoglobin S and a ceiling for total hemoglobin are considered.

Transfusion indications are clearly divided between a core group supported by strong evidence and a group whose benefit has not been demonstrated. At the top of the proven indications is the prevention of the first stroke in children identified as high-risk by transcranial Doppler through regular transfusion; this strategy has provided a striking reduction in risk by combining screening with preventive treatment.

Acute ischemic stroke, severe acute chest syndrome, and multiple organ failure are emergency indications. Preparation transfusion before moderate and high-risk surgical procedures reduces perioperative complications.

On the other hand, uncomplicated painful crisis, asymptomatic anemia, and routine priapism do not constitute transfusion indications.

Key considerations

• The differential diagnosis in the development of acute anemia in a patient with sickle cell disease is broad: aplastic crisis (with parvovirus B19, reticulocytopenia), splenic sequestration (especially in children, with rapid splenic enlargement), delayed hemolytic transfusion reaction, hyperhemolysis syndrome, bleeding, and accelerated hemolysis should be distinguished; treatments are entirely different.
• Hyperhemolysis syndrome and delayed hemolytic transfusion reaction may be continuations of each other; in hyperhemolysis, a distinguishing feature is the drop of hemoglobin BELOW the pre-transfusion level and that additional transfusion is harmful.
• Vaso-occlusive painful crisis and delayed hemolytic transfusion reaction may clinically be confused; a recent transfusion history and an unexpected drop in hemoglobin suggest the latter, and this distinction changes the transfusion decision.
• Acute chest syndrome may be confused with pneumonia, pulmonary embolism, and fat embolism; the severity and oxygenation status determine the choice between simple and exchange transfusion (relevant protocol).
• In a patient with sickle cell disease, neurological deficit can occur not only with ischemic stroke but also with intracranial hemorrhage, posterior reversible encephalopathy syndrome, and fat embolism; imaging provides differentiation, but exchange transfusion should not be delayed in ischemic stroke.
• In a patient on a chronic transfusion program, iron overload should be evaluated in case of fatigue and organ dysfunction; these findings can be overlooked if attributed to the disease itself (relevant protocol).
• In the case of failure to achieve the expected post-transfusion increase, alloimmunization, ongoing hemolysis, and hypersplenism are included in the differential diagnosis.

Why it matters

The principle of transfusion in sickle cell disease revolves around managing two variables simultaneously: the proportion of hemoglobin S and blood viscosity. The underlying problem of the disease is that hemoglobin S, which polymerizes under low oxygen conditions, stiffens and sickles the erythrocytes, blocking microcirculation.

Therefore, the treatment goal is to reduce the proportion of hemoglobin S in the circulation below the disease-causing threshold. However, a second risk arises while reaching this goal: as hemoglobin increases, blood viscosity rises, and in a viscous environment, sickle cells cause blockages more easily.

These two variables directly determine the choice of transfusion method. Simple transfusion can only lower the hemoglobin S proportion through dilution, so a significant amount of blood needs to be added for a meaningful reduction; this, in turn, raises total hemoglobin and viscosity.

Exchange transfusion, on the other hand, simultaneously removes the patient’s own cells, rapidly reducing the hemoglobin S proportion while keeping total hemoglobin constant. Therefore, in urgent and severe cases, especially in acute ischemic stroke and severe acute chest syndrome, exchange is preferred.

The same logic also explains why simple transfusion is avoided in patients with relatively high baseline hemoglobin. The rationale for determining indications is limited to situations where the benefit of transfusion has been proven, and the reason for this is the specific risks that transfusion carries in these patients.

Sickle cell patients receive numerous transfusions throughout their lifetime, and their alloimmunization rates are significantly higher than those of other patient groups. A major reason for this high rate is the differences in erythrocyte antigen distribution between the patient and donor populations; when products containing antigens not present in the patient are repeatedly given, antibody development is facilitated.

Once alloimmunization develops, finding compatible products becomes increasingly difficult, and a delay in transfusion in an emergency scenario can be life-threatening. Moreover, alloimmunization lays the groundwork for delayed hemolytic transfusion reactions and, in its most dangerous form, hyperhemolysis syndrome.

Therefore, guidelines recommend ensuring compatibility at least for Rh subgroups and the Kell antigen from the first transfusion; the fundamental principle here is that solving the problem is much more difficult than preventing it. Hyperhemolysis syndrome is the most striking example of why transfusion decisions in this disease need to be made with great care, and it requires management that is entirely contrary to intuition.

In this condition, hemoglobin drops below even the pre-transfusion level days after the transfusion; because not only the donor erythrocytes given but also the patient’s own erythrocytes are destroyed. The clinical picture gives the impression that 'more blood is needed'; however, additional transfusion worsens the condition by fueling hemolysis and can be fatal.

The correct approach is to avoid transfusion and switch to immunosuppressive treatment. Therefore, in a patient with sickle cell disease, an unexpected drop in hemoglobin after transfusion should always raise this possibility.

In the logic of chronic transfusion programs, the balance of benefit and risk is established over time. Regular transfusion in children found to be high risk through transcranial Doppler screening largely prevents the first stroke and prevents lifelong neurological damage; this is a gain that more than compensates for the risks of transfusion.

On the other hand, the program brings iron overload and alloimmunization; therefore, methods that reduce iron accumulation such as erythrocytapheresis, extended antigen matching, and chelation planning are integral parts of the program.

Critical complications

• Alloimmunization is common in patients with sickle cell disease; it makes finding compatible products more difficult, can delay emergency transfusion, and sets the stage for hemolytic reactions.
• Delayed hemolytic transfusion reaction appears days to weeks after transfusion with hemoglobin drop, jaundice, and elevated lactate dehydrogenase, and can be overlooked by being confused with vaso-occlusive crisis.
• Hyperhemolysis syndrome is a life-threatening complication in which both donor and the patient’s own erythrocytes are destroyed, hemoglobin drops below pre-transfusion levels, and additional transfusion worsens the condition.
• Hyperviscosity occurs with excessive elevation of hemoglobin and can trigger vaso-occlusive events, including stroke.
• Transfusional iron overload is inevitable in chronic programs and leads to damage to the heart, liver, and endocrine organs; erythrocytapheresis reduces this risk.
• Vascular access complications are seen especially in patients in chronic apheresis programs as central catheter infection and thrombosis.
• The risk of infection transmission increases overall in this group due to cumulative exposure; hepatitis vaccination and serological monitoring are recommended.
• Interrupting the chronic program leads to a renewed increase in stroke risk; the decision to stop requires expert evaluation.

Special considerations

• Children found to be high risk with transcranial Doppler: a chronic transfusion program is indicated for primary stroke prevention, and this is the strongest evidence-based transfusion indication for the disease; maintaining the screening program is critically important.
• Patients who have had a stroke: chronic transfusion is applied for secondary prevention; since the risk of recurrence increases when the program is stopped, the decision to discontinue requires expert evaluation.
• Patients scheduled for surgery: in moderate-to-high-risk procedures, increasing hemoglobin to approximately 10 g/dL with simple preoperative transfusion reduces perioperative complications; it is not necessary for low-risk minor procedures.
• Pregnant patients: transfusion indications during pregnancy are debatable, and routine prophylactic transfusion is not standard; the decision is made in partnership with perinatology and hematology, taking into account complication history and pregnancy course.
• Alloimmunized patients: finding compatible products becomes more difficult; the antibody profile should be recorded in the patient record, electronic system, and on a portable card, and pre-planning with the blood bank for emergencies is required.
• Patients with a history of hyperhemolysis syndrome: subsequent transfusions are very high risk; transfusion should only be considered in life-threatening situations and under immunosuppression, with expert decision. This history must be recorded.
• Children in the chronic transfusion program: growth, puberty, and endocrine development are affected by iron overload; chelation adherence and monitoring should be managed by pediatric hematology.
• Patients presenting with uncomplicated painful crises: there is no transfusion indication; treatment consists of pain management, hydration, and oxygenation, and unnecessary transfusion causes long-term harm.

Follow-up plan

The follow-up of a patient receiving transfusion for sickle cell disease includes both achieving treatment goals and early detection of transfusion-specific complications, and requires close cooperation between hematology and the blood bank. In a patient who receives a transfusion due to an acute event, the hemoglobin S level and total hemoglobin are measured after the procedure to document whether the targets have been achieved; special attention is paid to ensure that the total hemoglobin does not exceed the determined ceiling.

In patients in a chronic transfusion program, the hemoglobin S level is measured before each session to assess whether it remains within the target range, and the interval between sessions is adjusted accordingly. The most critical component of follow-up is the course of hemoglobin in the post-transfusion period.

Failure to achieve the expected increase or a decrease in hemoglobin in the following days is indicative of delayed hemolytic transfusion reaction and hyperhemolysis syndrome; since these conditions can be confused with vaso-occlusive crisis, these possibilities must be evaluated when a patient who has recently received a transfusion presents with pain, fatigue, and a drop in hemoglobin. In suspected hyperhemolysis, avoiding additional transfusion and urgently contacting hematology can be life-saving.

Alloimmunization screening should be carried out regularly, and all identified antibodies should be recorded in the patient file, electronic health record, and on a card that the patient can carry; this information ensures that a compatible product can be rapidly found in case of an emergency transfusion at another center. It should be confirmed that the need for extended antigen matching is specified with every product request.

Iron overload monitoring should not be neglected in patients receiving a chronic program: ferritin should be measured regularly, magnetic resonance-based liver and heart iron measurement should be performed at high values to make chelation decisions, and the patient’s adherence to chelation therapy should be evaluated at each visit; although iron accumulation is slower in patients undergoing erythrocytapheresis, monitoring should continue. Patients with a vascular access device should be assessed for catheter infection and thrombosis.

Completion of hepatitis vaccination and serological monitoring are recommended due to cumulative transfusion exposure. In children, transcranial Doppler screening should continue within the framework of the program, and growth and puberty should be monitored.

The patient and their family should be informed about why transfusion is limited to certain situations, why hemoglobin is not brought up to 'normal,' and which symptoms (jaundice, dark urine, increased fatigue, pain) should be reported after transfusion; this education can be decisive in the early recognition of conditions like hyperhemolysis.